Calamos Advisors
ASND icon

Calamos Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Calamos Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.52M Sell
15,390
-910
-6% -$204K 0.01% 604
2025
Q4 		$3.48M Buy
16,300
+9,850
+153% +$2.03M 0.01% 570
2025
Q3 		$1.28M Buy
+6,450
New +$1.2M ﹤0.01% 675

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Calamos Advisors's ASND Position: Q1 2026 in Review

Calamos Advisors reduced its Ascendis Pharma A/S (ASND) stake by 5.6% in Q1 2026, selling an estimated $204K and leaving 15,390 shares worth $3.52M. The position accounts for 0.01% of the portfolio, ranked #604.

Calamos Advisors first reported a position in ASND in Q3 2025 and has held it in 3 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Calamos Advisors held 15,390 shares of Ascendis Pharma A/S worth $3.52M as of Q1 2026.
  • Calamos Advisors sold 910 Ascendis Pharma A/S shares in Q1 2026, an estimated $204K.
  • Ascendis Pharma A/S made up 0.01% of Calamos Advisors's portfolio in Q1 2026, its #604 holding.
  • Calamos Advisors first reported a position in Ascendis Pharma A/S in Q3 2025 and has held it in 3 quarters since.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.